Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US53619R1023
Reset filter
Fri, 19.06.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Gr...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.06.2026       Lion Biotechnologies
US53619R1023

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Lion Biotechnologies
US53619R1023

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 21, 2026 (the “Date of Gran...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and C...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Lion Biotechnologies
US53619R1023

1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 16, 2026 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming con...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 24.02.2026       Lion Biotechnologies
US53619R1023

~30% Quarterly Revenue Growth Driven by Amtagvi Demand...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date o...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.02.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.02.2026       Lion Biotechnologies
US53619R1023

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 15, 2026 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.12.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 18, 2025 (the “Date o...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 20, 2025 (the “Date o...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Lion Biotechnologies
US53619R1023

Quarterly Revenue Growth of 13% to ~$68 Million ...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.10.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.09.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 29.08.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.08.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.08.2025       Lion Biotechnologies
US53619R1023

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.07.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Gr...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.06.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2025 (the “Date of Gr...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Lion Biotechnologies
US53619R1023

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.05.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 15, 2025 (the “Date of Gran...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 02.05.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Wed, 23.04.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible,...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 18.04.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.03.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 20, 2025 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 21, 2025 (the “Date o...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.02.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 10, 2025 (the “Date o...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.02.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company’s executive leadershi...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.12.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date o...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.09.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that senior leadership plans to prese...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.08.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 15, 2024 (the “Date of...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.07.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 18, 2024 (the “Date of Gr...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.06.2024       Lion Biotechnologies
US53619R1023

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.06.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2024 (the “Date of Gr...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.05.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences a...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.05.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 16, 2024 (the “Date of Gran...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.05.2024       Lion Biotechnologies
US53619R1023

SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Managem...
Read more
Lion Biotechnologies
Technical Analysis Termsheets Terminal
Permalink